Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHP Redux litigation

Executive Summary

Payments totaling $4.1 bil. were made in the first quarter, bringing American Home Product's total diet drug-related settlement pay-outs to approximately $8.2 bil. Since January, AHP has settled roughly 2,000 additional cases of the 10,000 remaining from claimants that opted out of the class action lawsuit. The company expects to make a total of $12.25 bil. in Redux-related payments (1"The Pink Sheet" Jan. 29, p. 18). AHP is in a net debt position of $3.4 bil. as of March 31

You may also be interested in...



AHP Sets Redux Liability Cost At $12 Bil.: 25% More Than Price Of Cyanamid

American Home Products' latest cost estimate for the Redux liability case is approximately 25% higher than the cash payment AHP made in 1994 to acquire American Cyanamid.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel